Zimmer Biomet Lands Medtronic Exec As Its New CEO
The orthopedic giant hired a well-respected medtech industry veteran as its new CEO, leading to some seat-jumping within Medtronic's executive ranks.
You may also be interested in...
Zimmer Biomet’s net sales were up 1.2% year-over-year in the second quarter. CEO Bryan Hanson said the ROSA Knee robotic surgery system is performing even better than expected since it launched earlier this year, and is expected to be an important revenue-driver in the future.
As Katarzyna Mazur-Hofsäss approaches her fifth anniversary as head of Zimmer Biomet's EMEA division, she chats with Medtech Insight about her concerns as medical device companies operating in Europe try to cope with the new regulatory environment and how the orthopedics giant is responding to new demands from health-care providers.
The numbers of medical device approvals were up in most regions outside the US and the biggest surge, by percentage, was in approvals from emerging markets and the so-called BRIC countries. It remains to be seen if the trend will continue in 2018, but many companies are already counting on important non-US approvals coming in the next year.